Genenta Science SPA (GNTA) News & EventsGNTAGenenta Science SPA

Genenta Science Enters €6M Financing Agreement with Sophia High Tech

Genenta Science announced that it has entered into a binding offer with Sophia High Tech, under which Genenta will fund Sophia through two reserved capital increases, with the goal of reaching a controlling stake upon the achievement of defined performance milestones. The transaction with Sophia High Tech would be completed in two phases and remains subject to confirmatory due diligence, required approvals, and definitive transaction documentation. Sophia High Tech is an aerospace and defense engineering and manufacturing company, headquartered in Somma Vesuviana, Italy. Genenta expects to fund a total of EUR 6M in two tranches, the second tranche being performance-driven. Sophia High Tech is projecting growing revenues. Sophia HT is already profitable and forecasts continued EBITDA growth in 2026, 2027 and beyond. The funds are expected to be used for materially scaling production capacity, accelerating technological differentiation, and strengthening commercial penetration.

Genenta Science Explores Collaboration Opportunities for Biotechnology Platform

Genenta Science announced that, with respect to its biotechnology platform, Genenta has been and continues to be actively engaged with DC Advisory to explore potential collaboration opportunities for the further development of its original biotechnology platform, which originated from research conducted by founder-scientists, Professor Luigi Naldini and Bernhard Gentner. To date, DC Advisory has not identified, and the company is not in any active discussions with, potential strategic partners regarding Temferon or its biotechnology platform. Genenta nevertheless intends to continue pursuing potential collaboration opportunities. "As a co-founder, I have never sold my shares in Genenta; in fact, I have increased my position by purchasing ADSs during open trading windows," said Pierluigi Paracchi, CEO of Genenta. "The founder-scientists are currently holders of Genenta's ordinary shares and Genenta opposes any sale of shares by the founder-scientists unless and until Temferon receives meaningful third-party validation. Given the current uncertainty surrounding the future development of Temferon, the founder-scientists have been aware of Genenta's need to broaden its strategic path, even if they have not fully shared that view. We are building Genenta into an industrial aggregator operating in some of the most strategically sensitive sectors of the modern economy - biotech, defense, aerospace, and cybersecurity. Think of us as a forge: we identify the most promising scale-ups in sectors that matter for national security, and we provide them with capital, structure, indirect access to the U.S. public markets through our Nasdaq listing, and the industrial capabilities needed to help them become national champions. We are pursuing this strategy not in spite of the market, but ahead of it. Italy produces extraordinary technology and industrial value. Too often, however, it fails to retain them. We believe that this value creation should remain here. Above all, this strategic evolution is intended to serve the best interests of our shareholders, and we remain fully focused on creating long-term shareholder value through disciplined execution and the selective acquisition of high-quality industrial assets."